Genetics Squared - evolutionary drug development

Ann Arbor, MI November 22, 2008 Bill Worzel, President and CEO of Genetics Squared will speak at TiECon Midwest converence on Saturday, November 22, 2008. He will be present at the session titled The New Frontier: Opportunities in Life Sciences and Biotechnology on the application of Genetics Squared’s Evolver™ technology to develop molecular tests for clinical use. By combining Evolver’s cutting edge computing technology with careful clinical and scientific analysis to produce simple, precise diagnostic tests, Genetics Squared will make a significant impact on the healthcare market.

Canton, MI November 20, 2008 Genetics Squared's CEO, Bill Worzel was a panelist at the MichBio Expo Policy Summit on November 18, 2008 at the Rock Financial Showplace in Novi, Michigan. The Summit was convened to discuss the future of biotechnology development in Michigan. Each panelist made specific recommendations on what the State could do to support the growth of the biotech industry in Michigan. Mr. Worzel stressed the importance of focused support for both young and growing companies, patience by the State in the development of the industry and the importance of making entrepreneurial opportunities available to new graduates as a way to retain talent and to guarantee the long term survival and growth of the biotech industry.

Ann Arbor, MI October 28, 2008 - article in Business Review about Genetics Squared and Armune's lab joint venture

Ann Arbor, MI, August 4, 2008 Bill Worzel Gives Seminar on Genetic Programming at the National Center for Integrative Biomedical Informatics “Tools and Technology” Series more (pdf)

Ann Arbor, MI, July 30, 2008- NIH Awards Research Grant to Genetics Squared

The National Institutes of Health have awarded Genetics Squared $162,300 in grant money. more (pdf)
May, 2008, Genetics Squared’s Chief Medical Officer Selected for the Sanford Project Advisory Council whose recommendation will Influence $400 million research decisions
May, 2008 Bill Worzel, Genetics Squared's CEO organized the annual conference GP Theory & Practice with Dr. Rick Riolo of the Center for the Study of Complex Systems at the University of Michigan and Dr. Terry Soule from the University of Idaho. Worzel presented the paper "A Population Based Study Of Evolutionary Dynamics In Genetic Programming" written with A.A. Almal and C.D.MacLean of Genetics Squared.
January, 2008 Case Study: Using Genetics Squared’s Evolve^TM Technology to Identify Predictive Biomarkers for Legionella pneumophila Pathogenicity.
September 2007 Poster (pdf) presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-20, Chicago. Schuren et al. Identification of predictive markers for Legionella pneumophila pathogenicity.
June 1-5, 2007 Genetics Squared attended ASCO, American Society of Clinical Oncology, Chicago, Illinois
May 15, 2007 Bill Worzel, President and CTO, facilitated elite, by invitation only, Genetic Programming Theory and Practice V workshop, May 17-19, 2007, Ann Arbor, MI more
September 25, 2006 Genetics Squared Awarded $1.6 million from the 21st Century Job Fund read more

September 25, 2006
Genetics Squared Awarded $1.6 million from the 21st Century Job Fund
read more

June 19-21, 2006, San Francisco, CA
CHI's Beyond Genome 2006
Chief Technology Officer, Bill Worzel, will discuss the use of genetic programming to discover a 3-gene signature of metastasis in bladder cancer. This signature identifies nodal metastases from primary tumor tissue from quantitative RT-PCR data. The method used to discover this signature is described and the broader significance of this approach to clinical applications including personalized medicine is discussed.

June 18-22, 2006, Philadelphia, PA
The Drug Industry Association Annual Meeting
Genetics Squared will participate in the session chaired by Dr. Terry Osborn where we will discuss "The Use of Genetic Programming to Identify Biomarkers Associated with Metastasis in Bladder Cancer." This is a collaboration with the Richard Cote Laboratory of the University of Southern California that discovered a simple set of biomarkers taken from quantitative RT-PCR data that identify nodal involvement from primary tumor tissue. The technology used to develop this signature and its potential clincal impact will be discussed.